PH12015502042A1 - Use of linagliptin in cardio-and renoprotective antidiabetic therapy - Google Patents

Use of linagliptin in cardio-and renoprotective antidiabetic therapy

Info

Publication number
PH12015502042A1
PH12015502042A1 PH12015502042A PH12015502042A PH12015502042A1 PH 12015502042 A1 PH12015502042 A1 PH 12015502042A1 PH 12015502042 A PH12015502042 A PH 12015502042A PH 12015502042 A PH12015502042 A PH 12015502042A PH 12015502042 A1 PH12015502042 A1 PH 12015502042A1
Authority
PH
Philippines
Prior art keywords
cardio
renoprotective
linagliptin
antidiabetic therapy
therapy
Prior art date
Application number
PH12015502042A
Other languages
English (en)
Other versions
PH12015502042B1 (en
Inventor
Johansen Odd-Erik
Von Eynatten Maximilian
Klein Thomas
Woerle Hans-Juergen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50277246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12015502042(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PH12015502042A1 publication Critical patent/PH12015502042A1/en
Publication of PH12015502042B1 publication Critical patent/PH12015502042B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH12015502042A 2013-03-15 2015-09-10 Use of linagliptin in cardio-and renoprotective antidiabetic therapy PH12015502042B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13159624 2013-03-15
EP13177311 2013-07-19
PCT/EP2014/055113 WO2014140284A1 (en) 2013-03-15 2014-03-14 Use of linagliptin in cardio- and renoprotective antidiabetic therapy

Publications (2)

Publication Number Publication Date
PH12015502042A1 true PH12015502042A1 (en) 2016-01-18
PH12015502042B1 PH12015502042B1 (en) 2016-01-18

Family

ID=50277246

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015502042A PH12015502042B1 (en) 2013-03-15 2015-09-10 Use of linagliptin in cardio-and renoprotective antidiabetic therapy

Country Status (14)

Country Link
US (9) US20140274889A1 (enExample)
EP (4) EP4364796A3 (enExample)
JP (4) JP2016510795A (enExample)
KR (2) KR20210099201A (enExample)
CN (2) CN110075098A (enExample)
AU (2) AU2014230096C1 (enExample)
BR (1) BR112015020209A2 (enExample)
CA (1) CA2903577C (enExample)
CL (1) CL2015002369A1 (enExample)
EA (1) EA037712B1 (enExample)
IL (1) IL240064A0 (enExample)
MX (2) MX2015011466A (enExample)
PH (1) PH12015502042B1 (enExample)
WO (1) WO2014140284A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
MX2018011813A (es) * 2016-03-28 2019-01-24 Intercept Pharmaceuticals Inc Medicina obtenida mediante la combinacion de agonista fxr y arb.
EP3468562A1 (en) * 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
US20210299129A1 (en) * 2018-07-17 2021-09-30 Boehringer Ingelheim International Gmbh Cardiosafe Antidiabetic Therapy
MX2021000554A (es) * 2018-07-17 2021-03-29 Boehringer Ingelheim Int Tratamiento antidiabetico cardiovascular y renal seguro.
CN111333626B (zh) * 2018-12-18 2022-10-18 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物及其用途
JPWO2022244846A1 (enExample) * 2021-05-19 2022-11-24

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
MXPA03007349A (es) 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP2308878A3 (de) 2002-08-21 2011-10-26 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-Amino-Piperidin-1-YL] -Xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238470A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10251927A1 (de) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
DE10327439A1 (de) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10359098A1 (de) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
CA2555050C (en) 2004-02-18 2017-11-28 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthine derivatives, the production thereof and the use in the form of a dpp-iv inhibitor
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
JP2007531780A (ja) 2004-04-10 2007-11-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な２−アミノ−イミダゾ［４，５−ｄ］ピリダジン−４−オン及び２−アミノ−イミダゾ［４，５−ｃ］ピリダジン−４−オン、その製法及び医薬としての使用
DE102004022970A1 (de) 2004-05-10 2005-12-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
KR20070099527A (ko) 2004-10-08 2007-10-09 노파르티스 아게 유기 화합물의 조합물
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20080318922A1 (en) 2004-12-24 2008-12-25 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic Pyrrole Derivatives
MX2007011453A (es) * 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
US7863307B2 (en) 2005-07-01 2011-01-04 Merck Sharp & Dohme Process for synthesizing a CETP inhibitor
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20090192138A1 (en) 2005-12-23 2009-07-30 Daniel Kaspar Baeschlin compounds
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32177A (es) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
US20100256153A1 (en) * 2009-03-27 2010-10-07 Bristol-Myers Squibb Company Methods for preventing or reducing risk of mortality
NZ598170A (en) * 2009-10-02 2014-06-27 Boehringer Ingelheim Int Pharmaceutical compositions comprising bi-1356 and metformin
EP3646859A1 (en) * 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20130303462A1 (en) * 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174768A1 (en) * 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada

Also Published As

Publication number Publication date
EP4364796A2 (en) 2024-05-08
CL2015002369A1 (es) 2016-02-19
EP2968344A1 (en) 2016-01-20
EP3409279A1 (en) 2018-12-05
JP2016510795A (ja) 2016-04-11
NZ710249A (en) 2021-04-30
KR20210099201A (ko) 2021-08-11
IL240064A0 (en) 2015-09-24
US20190192523A1 (en) 2019-06-27
US20170065596A1 (en) 2017-03-09
JP2021095409A (ja) 2021-06-24
US20160089373A1 (en) 2016-03-31
EP4364796A3 (en) 2024-07-24
MX2015011466A (es) 2016-01-22
US20240033270A1 (en) 2024-02-01
EA201500934A1 (ru) 2016-03-31
EA037712B1 (ru) 2021-05-13
AU2014230096C1 (en) 2019-08-29
US20250025470A1 (en) 2025-01-23
AU2019203445A1 (en) 2019-06-06
CA2903577A1 (en) 2014-09-18
JP2025115998A (ja) 2025-08-07
US20180263990A1 (en) 2018-09-20
EP3744327A1 (en) 2020-12-02
KR20150128726A (ko) 2015-11-18
CA2903577C (en) 2023-10-17
AU2014230096B2 (en) 2019-02-21
BR112015020209A2 (pt) 2017-07-18
CN110075098A (zh) 2019-08-02
CN105188706A (zh) 2015-12-23
US20200338086A1 (en) 2020-10-29
JP2019112409A (ja) 2019-07-11
US20140274889A1 (en) 2014-09-18
MX2021014242A (es) 2022-01-06
PH12015502042B1 (en) 2016-01-18
US20210205316A1 (en) 2021-07-08
WO2014140284A1 (en) 2014-09-18
AU2014230096A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
IN2014DN09782A (enExample)
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
MY187540A (en) Compounds active towards bromodomains
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
WO2015009726A3 (en) Medical uses of cd38 agonists
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
ZA202503350B (en) Semaglutide in medical therapy
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
HK1206985A1 (en) Combination therapy of anti-mif antibodies and chemotherapeutics
WO2014012025A3 (en) Igf-1 proteins and therapeutic uses thereof
MX362111B (es) Un metodo para mejorar la funcion hepatica.
PH12020500472A1 (en) Autotaxin inhibitor compounds
HK1207008A1 (en) Use of thymosin alpha for treatment of purulent rhinosinusitis
HK1242990A1 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
UA79303U (ru) Применение таурина как средства стабилизации концентрации итраконазола в плазме крови при лечении грибковых заболеваний